Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The company has submitted a request for a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration...
Mira Pharmaceuticals, Inc. (NASDAQ:MIRA) today announced that it has selected neuropathic pain as the primary indication for it...
https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_08262024_MIRA_Sorensen.pdf
MIRA Pharmaceuticals stock surges on promising preclinical results of oral ketamine analog, Ketamir-2, showing 100% pain thresh...
- SEC Filing
MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) "MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical c...
